This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (15) Citing Articles via Google Scholar Google Scholar Articles by Ohlsen, R. I. Articles by Pilowsky, L. S. Search for Related Content PubMed PubMed Citation Articles by Ohlsen, R. I. Articles by Pilowsky, L. S. Social Bookmarking                   What's this?

The place of partial agonism in psychiatry: recent developments

Institute of Psychiatry, De Crespigny Park, London, UK., r.ohlsen{at}iop.kcl.ac.uk

L. S. Pilowsky

Institute of Psychiatry, De Crespigny Park, London, UK.

Drugs used to treat psychiatric disorders, although effective, are often restricted by adverse events. The use of partial agonists for treating hypertension was found to limit some of the side-effects in some patients. This led to the investigation of partial agonists as a treatment modality in psychiatric disorders. Partial agonists have a lower intrinsic efficacy than full agonists leading to reduced maximum response. They can act as antagonists by competing for receptor binding with full agonists. The level of activity depends on the level of endogenous receptor activity. Buprenorphine, a partial agonist at the mu-opioid receptor, is used to treat patients with addiction and decreases the symptoms of withdrawal and risks of overdose and intoxication. The anxiolytic buspirone shows partial agonism at 5-HT_1A receptors, and this seems to provide anxioselective effects, without inducing extrapyramidal side-effects, convulsions, tolerance or withdrawal reactions. In schizophrenia, partial dopamine agonism results in antagonistic effects at sites activated by high concentrations of dopamine and agonistic effects at sites activated by low concentrations of dopamine. This stabilizes the dopamine system to effect antipsychotic action without inducing adverse motor or hormonal events. Aripiprazole is the first ‘dopamine system stabilizer’, and the data are promising, with efficacy at least equivalent to that with current atypical antipsychotics but fewer of the troublesome side-effects. Partial agonists seem to provide a way to fine-tune the treatment of psychiatric disorders by maximizing the treatment effect while minimizing undesirable adverse events.

Key Words: addiction • anxiety • aripiprazole • buprenorphine • partial agonist • psychiatric disorders • schizophrenia

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Yamauchi, J. Dostal, H. Kimura, and K. P. Strohl Effects of buspirone on posthypoxic ventilatory behavior in the C57BL/6J and A/J mouse strains J Appl Physiol, August 1, 2008; 105(2): 518 - 526. [Abstract] [Full Text] [PDF]

				D. F. Klein The Loss of Serendipity in Psychopharmacology JAMA, March 5, 2008; 299(9): 1063 - 1065. [Full Text] [PDF]